CHICAGO, Sept. 11, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted ...
MAIA Biotechnology (MAIA) highlights efficacy data from its Phase 2 clinical trial, THIO-101, evaluating ateganosine sequenced with the immune checkpoint inhibitor cemiplimab in patients with advanced ...
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback